NEWS: Update

Medical Marketing and Media,  Apr 2008  

• E-mail
• Print
• Link

Schering-Plough's "49 Plan," an aggressive seven-week sales push allegedly aimed at shoring up Zetia prescriptions by offering docs meals and entertainment, came under congressional scrutiny after it was reported on by the StarLedger blog Pharmalot.

The FDA made deputy commissioner Janet Woodcock permanent director of the Center for Drug Evaluation and Research following a national search to fill the slot. Woodcock, who stepped in as acting director of the center following Stephen Galson's elevation to surgeon general last fall, previously headed CDER from 1994-2005.

Amgen and J&J can continue to market their anemia drugs for cancer patients but their use should be restricted due to concerns of increased risk of tumor growth and death, an FDA advisory panel ruled.

Eli Lilly strongly denied that incoming CEO John Lechleiter encouraged off-label promotion of the company's schizophrenia treatment Zyprexa to children and teens in an email he sent in 2003, as reported by The New York Times.

Copyright Haymarket Media, Inc. Apr 2008
Provided by ProQuest Information and Learning Company. All rights Reserved